» Articles » PMID: 31403076

Tanshinones: First-in-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle of for Antibiotic Therapy

Overview
Journal ACS Cent Sci
Specialty Chemistry
Date 2019 Aug 13
PMID 31403076
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The type 3 secretion system (T3SS) found as cell-surface appendages of many pathogenic Gram-negative bacteria, although nonessential for bacterial survival, is an important therapeutic target for drug discovery and development aimed at inhibiting bacterial virulence without inducing antibiotic resistance. We designed a fluorescence-polarization-based assay for high-throughput screening as a mechanistically well-defined general strategy for antibiotic discovery targeting the T3SS and made a serendipitous discovery of a subset of tanshinones-natural herbal compounds in traditional Chinese medicine widely used for the treatment of cardiovascular and cerebrovascular diseases-as effective inhibitors of the biogenesis of the T3SS needle of multi-drug-resistant . By inhibiting the T3SS needle assembly and, thus, cytotoxicity and pathogenicity, selected tanshinones reduced the secretion of bacterial virulence factors toxic to macrophages , and rescued experimental animals challenged with lethal doses of in a murine model of acute pneumonia. As first-in-class inhibitors with a demonstrable safety profile in humans, tanshinones may be used directly to alleviate -associated pulmonary infections without inducing antibiotic resistance. Since the T3SS is highly conserved among Gram-negative bacteria, this antivirulence strategy may be applicable to the discovery and development of novel classes of antibiotics refractory to existing resistance mechanisms for the treatment of many bacterial infections.

Citing Articles

A Supramolecular Antibiotic Targeting Drug-Resistant through the Inhibition of Virulence Factors and Activation of Acquired Immunity.

Jiang C, Zheng L, Yan Y, Wang M, Liu X, Dai J ACS Appl Mater Interfaces. 2024; 16(32):41828-41842.

PMID: 39088848 PMC: 11331443. DOI: 10.1021/acsami.4c06665.


Using next generation antimicrobials to target the mechanisms of infection.

Gadar K, McCarthy R NPJ Antimicrob Resist. 2024; 1(1):11.

PMID: 38686217 PMC: 11057201. DOI: 10.1038/s44259-023-00011-6.


SLC39A10 promotes malignant phenotypes of gastric cancer cells by activating the CK2-mediated MAPK/ERK and PI3K/AKT pathways.

Ren X, Feng C, Wang Y, Chen P, Wang S, Wang J Exp Mol Med. 2023; 55(8):1757-1769.

PMID: 37524874 PMC: 10474099. DOI: 10.1038/s12276-023-01062-5.


Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems.

Blasey N, Rehrmann D, Riebisch A, Muhlen S Front Cell Infect Microbiol. 2023; 12:1065561.

PMID: 36704108 PMC: 9872159. DOI: 10.3389/fcimb.2022.1065561.


Research Progress on Small Molecular Inhibitors of the Type 3 Secretion System.

Lv C, Li Y, Wei Y, Wang J, Yu H, Gao F Molecules. 2022; 27(23).

PMID: 36500441 PMC: 9740592. DOI: 10.3390/molecules27238348.


References
1.
Sawa T, Yahr T, Ohara M, Kurahashi K, Gropper M, Wiener-Kronish J . Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med. 1999; 5(4):392-8. DOI: 10.1038/7391. View

2.
Lu W, Starovasnik M, Dwyer J, Kossiakoff A, Kent S, Lu W . Deciphering the role of the electrostatic interactions involving Gly70 in eglin C by total chemical protein synthesis. Biochemistry. 2000; 39(13):3575-84. DOI: 10.1021/bi992292q. View

3.
Dawson P, Kent S . Synthesis of native proteins by chemical ligation. Annu Rev Biochem. 2000; 69:923-60. DOI: 10.1146/annurev.biochem.69.1.923. View

4.
Stover C, Pham X, Erwin A, Mizoguchi S, Warrener P, Hickey M . Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature. 2000; 406(6799):959-64. DOI: 10.1038/35023079. View

5.
Owicki J . Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen. 2000; 5(5):297-306. DOI: 10.1177/108705710000500501. View